Praxair, Inc. (NYSE:PX)went down -0.20% during trading on the US exchange where it had a trading capacity of 1.58M shares. The company’s shares were closed at $116.72 . The stock has an operating margin of 21.20% and a net profit margin of 14.20% This appreciation has taken its price 11.90% above the 52-week low. The stock hit 1-yearhigh at $123.65 and a low of $104.30 in the same period.

Praxair, Inc. (NYSE:PX) Flood of Opinions

Praxair, Inc. (NYSE:PX) right now sits at consensus rating of 2.00 while 6 analysts have advocated the shares as ‘BUY’, 2 calls it an ‘OUTPERFORM’ and 12 suggest ‘HOLD’. The mean PT for this stock is at $1.60 while the max. level suggested by the brokerage firms is $1.60 and min. PT is $1.60. The mean PT is calculated considering the consensus of 1 analysts.

Edwards Lifesciences Corporation (NYSE:EW) went up 0.93% during trading on the US exchange when it had traded 1.57M shares. The company’s shares were closed at 93.60. The stock has a quick ratio of 3.50 and a current ratio of 4.20 . This appreciation has taken its price 15.38% above the 52-week low. The stock hit 1-yearhigh at $121.75 and a low of $81.12 in the same period.

Edwards Lifesciences Corporation (NYSE:EW) Analyst’s Consensus Price Estimates

It is widely believed that the more practical proxy for the market’s expectations is analyst’s consensus price estimates. The mean PT for this stock is at $115.36 while the max. level suggested by the brokerage firms is $140.00 and min. PT is $80.00. The mean PT is calculated considering the consensus of 21 analysts. EW right now sits at consensus rating of 2.00 while 10 analysts have advocated the shares as ‘BUY’, 8 calls it an ‘OUTPERFORM’ and 4 suggest ‘HOLD’.

Edwards Lifesciences Corporation (NYSE:EW): Past & Future Earnings

The mean revenue estimate for the current fiscal period ending March 2017 is $779.02M by 20 brokerage firms. The average revenue estimate for the year ending December 2017 is $3.27B by 23 analysts. Wall Street is forward looking. Therefore, stock prices are sometime established based on the expectations that prospective investors have for the future earnings power of the firm. In a similar way, Edwards Lifesciences Corporation (NYSE:EW) last announced results for quarter ended on 31 Dec 2016, disclosing EPS of $0.75. The reported earnings per share topped the analyst’s consensus by $0.03 with the percentage difference between estimated and actual earnings arriving at 4.20%.